Inventor
Hans G. KLINGEMANN
Inventor
US
Overview
Patents· 25 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes26%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations23%
C07KPeptides22%
C12NMicroorganisms or enzymes21%
Y02ATechnologies for adaptation to climate change4%
A01KAnimal husbandry1%
C12MApparatus for enzymology or microbiology1%
G01NInvestigating or analysing materials by determining their chemical or physical properties1%
PatentTitleYear
12,584,138Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies202612,516,093Recombinant erIL-15 NK cells202612,498,363Combined invasion and cytotoxicity assay using chemokine secreting target cells202512,473,348Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells202512,473,347Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells202512,435,122Fc-epsilon CAR202512,403,178Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on NK cell activity)202512,384,852Genetically modified NK-92 cells having a safety switch202512,378,300Elimination of CD19-positive lymphoid malignancies by CD19-car expressing NK cells202512,365,874Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors202512,180,283Anti-B7-H4 chimeric antigen receptor-modified NK-92 cells202412,109,238Chimeric antigen receptor-modified NK-92 cells202412,064,450Tumoricidal and antimicrobial compositions and methods202411,992,504Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment202411,975,027Tumoricidal and antimicrobial compositions and methods202411,813,292Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on NK cell activity)202311,643,452Fc-epsilon car202311,547,727Chimeric antigen receptor-modified NK-92 cells202311,439,697Nant cancer vaccine202211,364,265Recombinant erIL-15 NK cells202211,304,977Tumoricidal and antimicrobial compositions and methods202211,230,699Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors202211,213,547Tumoricidal and antimicrobial compositions and methods202211,207,392Coordinated multi-prong cancer therapy202111,207,350Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2026Patents assigned to IMMUNITYBIO INC (23)· patent assignee history
2021–2025Patents assigned to NANTKWEST INC (6)· patent assignee history
2021–2026Patents assigned to NANTCELL INC (4)· patent assignee history
2021–2022Patents assigned to NANT HOLDINGS IP LLC (2)· patent assignee history
2021–2026Based in US· patent location history
2022–2026Patents assigned to NANTBIO INC (2)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| IMMUNITYBIO INC | 23 | 2021–2026 |
| NANTKWEST INC | 6 | 2021–2025 |
| NANTCELL INC | 4 | 2021–2026 |
| NANT HOLDINGS IP LLC | 2 | 2021–2022 |
| NANTBIO INC | 2 | 2022–2026 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 25 | 2021–2026 |